Loading clinical trials...
Loading clinical trials...
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-07923568 IN ADULT PARTICIPANTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTION
Conditions
Interventions
Drug: PF-07923568
Locations
6
United States
Orlando Clinical Research Center
Orlando, Florida, United States
Genesis Clinical Research, LLC
Tampa, Florida, United States
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, United States
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas, United States
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Start Date
October 30, 2023
Primary Completion Date
July 3, 2024
Completion Date
July 3, 2024
Last Updated
July 19, 2024
NCT07154901
NCT07165015
NCT06693765
NCT06352411
NCT06835127
NCT07445906
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions